Skip to content

Effectiveness of Immune-Suppressants for Dry Eyes in Sj?gren?s

Effectiveness of systemic immunosuppressants for Dry-eyes in Sjogren disease. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093557
Enrollment
30
Registered
2025-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M350- Sicca syndrome [Sjogren]

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Hyderabad Eye Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of Sjogrens syndrome based on the American European Consensus Group 2002 revised criteria which requires the presence of at least 4 of 6 criteria or 3 of 4 objective criteria. The 6 criteria include - subjective and objective ocular dryness - subjective and objective evidence of salivary gland involvement (as determined by sialometry, sialography, or salivary gland scintigraphy) -presence of SSA/Ro, SSB/La, or both -positive minor salivary gland biopsy. A mandatory criterion for the diagnosis of primary SS was either positive serology (SSA or SSB) or positive minor salivary gland biopsy result.

Exclusion criteria

Exclusion criteria: - Pregnant and nursing mothers - Ocular infections, and ocular or refractive surgery in the last three months - Trauma to the globe, contact lens users. - Chronic users of any systemic or topical drugs causing dry eyes, such as antihistamines, anticholinergics, beta-blockers, diuretics, antidepressants, antipsychotics, and hormone replacement therapy, birth control pills or intrauterine devices (IUD) - Women with surgical menopause, the paediatric population, and psychiatric patients

Design outcomes

Primary

MeasureTime frame
Improvement in symptoms (OSDI) and signs (Ocular surface staining scores) at 6 months as compared with baseline. A minimum of 10% reduction will be taken as improvement.Timepoint: 6 months

Secondary

MeasureTime frame
1. Improvement in OSDI and in Ocular surface staining scores at 3 and 12 months 2. Improvement in Schirmer and Flourescein break-up score at 3, 6 and 12 months 3. Reduced frequency of adjuvants (lubricants) at 3, 6 and 12 monthsTimepoint: 3,6 and 12 months

Countries

India

Contacts

Public ContactDr Smruti Rekha Priyadarshini

L V Prasad Eye Institute

drsmruti@lvpei.org7894384444

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026